That we will.
Your theory is as reasonably as any other. In fact my very first suspicion, was that the BOD wants a quick resolution and the opportunity to bank some money while MT wanted to take it further. Was there any mention of Pre Clinical work on other conditions in the Quarterly ? I cant be bothered checking at the moment.
No matter what shenanigans may be going on, ODD will make Pharmaust a very attractive proposition.
Just guessing everyone, so don't take these comments to seriously. But it would explain a host of curiosities.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1274
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.010(4.88%) |
Mkt cap ! $95.68M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.0¢ | 21.5¢ | $266.0K | 1.235M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 372331 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 159805 | 5 |
View Market Depth
| Last trade - 10.48am 15/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |